Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab open-label study in refractory recurrent pregnancy loss
jRCTs041250083Recruiting
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of adalimumab in recurrent miscarriage (RPL). Primary endpoint: Change in serum TNF-alpha levels. Started Feb 2026; status: recruiting.
02
Drugs
03
Conditions
recurrent miscarriage (RPL)
Beyond the preview
Go deeper on jRCTs041250083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041250083.